Mixed IQWiG views on Gilead's Genvoya

11 April 2016

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined in an early benefit assessment whether Genvoya (elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide) offers an added benefit for patients in comparison with the appropriate comparator therapy treatment for adults and adolescents infected with HIV-1.

Genvoya, essentially a safer alternative to Truvada (emtricitabine and tenofovir) from US biotech giant Gilead Sciences (Nasdaq: GILD), has been approved in Europe and in the USA since last fall (The Pharma Letter November 23, 2015).

According to the IQWiG’s findings, there is a hint of a minor added benefit for pre-treated women without indication for a treatment switch, but not for men. Negative effects predominate in treatment-naive adults, irrespective of sex. Here IQWiG sees a hint of lesser benefit in comparison with the comparator therapy. There were no data for adolescents.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK